Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy in the Elderly

BACKGROUND Hypertrophic obstructive cardiomyopathy is a genetic disorder treated with septal reduction therapy, either alcohol septal ablation or septal myectomy (SM). Historically older patients have been presumed to be poor candidates for SM and thus referred directly for alcohol septal ablation in some centers. We reviewed our experience with SM in older patients. METHODS We identified 100 patients at our institution who underwent SM for hypertrophic obstructive cardiomyopathy from 2015 to 2020. Demographic and clinical characteristics and outcomes of patients 65 years or older were compared with patients younger than 65. RESULTS Sixty-five patients were in the <65 group and 35 patients in the >= 65 group. Both groups had similar preoperative peak stress left ventricular out flow tract gradients (129 mm Hg vs 110 mm Hg, P < .001). Most patients in both groups hadmoderate to severe mitral regurgitation on preoperative stress echocardiography. The elderly group was more likely to have coronary artery bypass graft as a concomitant procedure (37% vs 8%, P <.001). Only 1 death occurred in the series secondary to a pulmonary embolism. At the 30-day follow-upon stress echocardiography,peak stress gradients were normal in both groups(21 and 20 mm Hg, respectively; P <.001), and 88% of all patients had trace to mild mitral regurgitation. CONCLUSIONS Properly selected older patients can safely undergo SM with excellent outcomes similar to younger patients. Relief of left ventricular outflow tract obstruction and correction of mitral regurgitation are reliably achieved in both groups. Advanced age should not be a strict criteria for selecting septal reduction therapy approach. (C) 2022 by The Society of Thoracic Surgeons